Entering text into the input field will update the search result below

The FDA says it conducted an assessment of Johnson & Johnson (JNJ -0.2%) and Boehringer...

Nov. 02, 2012 1:37 PM ETJohnson & Johnson (JNJ) StockJNJBy: David Yelle, SA News Editor3 Comments
The FDA says it conducted an assessment of Johnson & Johnson (JNJ -0.2%) and Boehringer Ingelheim's Pradaxa using insurance claims and administrative data from its safety surveillance program, and found no evidence that the drug increased risk of bleeding when compared with warfarin. The agency launched an investigation of Pradaxa - which is approved to reduce the risk of stroke and embolism in patients with atrial fibrillation - last year after receiving reports of serious bleeding events in patients using the drug.

Recommended For You

About JNJ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JNJ--
Johnson & Johnson